Market closed

Alkermes/$ALKS

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Alkermes

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Ticker

$ALKS

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Dublin, Ireland

Employees

2,100

Website

www.alkermes.com

Alkermes Metrics

BasicAdvanced

$4.6B

14.39 $1.97

0.42 -

Price and volume

Market cap

$4.6B

Beta

0.42

52-week high

$32.88

52-week low

$22.90

Average daily volume

1.5M

Financial strength

Current ratio

3.489

Quick ratio

2.861

Long term debt to equity

22.121

Total debt to equity

22.353

Interest coverage (TTM)

13.28%

Management effectiveness

Return on assets (TTM)

8.98%

Return on equity (TTM)

29.23%

Valuation

Price to earnings (TTM)

14.391

Price to revenue (TTM)

3.143

Price to book

3.55

Price to tangible book (TTM)

3.8

Price to free cash flow (TTM)

15.007

Growth

Revenue change (TTM)

-5.37%

Earnings per share change (TTM)

55.25%

3-year revenue growth (CAGR)

10.05%

3-year earnings per share growth (CAGR)

50.99%

What the Analysts think about Alkermes

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Alkermes stock.

Alkermes Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Alkermes Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Alkermes News

AllArticlesVideos

Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth

Seeking Alpha·2 months ago

Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript

Seeking Alpha·3 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALKS

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Alkermes stock?

Alkermes (ALKS) has a market cap of $4.6B as of January 15, 2025.

What is the P/E ratio for Alkermes stock?

The price to earnings (P/E) ratio for Alkermes (ALKS) stock is 14.39 as of January 15, 2025.

Does Alkermes stock pay dividends?

No, Alkermes (ALKS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Alkermes dividend payment date?

Alkermes (ALKS) stock does not pay dividends to its shareholders.

What is the beta indicator for Alkermes?

Alkermes (ALKS) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.